Torg-Winchester syndrome

Torg-Winchester syndrome, also known as nodulosis-arthropathy-osteolysis syndrome or multicentric osteolysis with nodulosis and arthropathy (MONA), is an extremely rare inherited skeletal disorder caused by mutations in the MMP2 gene, which encodes matrix metalloproteinase 2. This enzyme plays a critical role in the breakdown and remodeling of extracellular matrix components, particularly collagen. The condition was historically described as separate entities — Torg syndrome and Winchester syndrome — but they are now recognized as part of the same disease spectrum. The disorder primarily affects the musculoskeletal system and connective tissues. Key clinical features include progressive multicentric osteolysis (destruction of bone in multiple sites, particularly the hands and feet), severe arthropathy (joint disease) with joint contractures, and subcutaneous nodules on the palms and soles. Patients may also develop osteoporosis, coarsened facial features, gum hypertrophy, and skin changes. The osteolysis typically begins in childhood and can lead to significant disability due to bone resorption and joint destruction. Cardiac involvement, including valvular abnormalities, has been reported in some cases. There is currently no cure or disease-specific treatment for Torg-Winchester syndrome. Management is supportive and symptomatic, focusing on orthopedic interventions, physical therapy to maintain joint mobility, pain management, and surgical correction of skeletal deformities when necessary. Bisphosphonates have been tried in some cases to slow bone loss, though evidence for their efficacy remains limited. Regular monitoring by a multidisciplinary team including orthopedics, rheumatology, dermatology, and cardiology is recommended.

Common questions about Torg-Winchester syndrome